; Merck & Co. Inc) and a bivalent (Cervarix™; GlaxoSmithKline) vaccine. Protection against HPV 23 infection and associated disease is observed for at least 6.4 years following immunization with the bivalent 24 vaccine and for at least 8.5 years with the HPV 16 L1 virus-like particle of the quadrivalent vaccine. HPV 25 vaccines induce robust immune memory, as evidenced by recall of responses after revaccination, suggesting 26 that immunization will afford long-lasting protection. An immunological marker for ongoing protection from 27 infection would provide information to help establish best-practice deployment of these vaccines. However, 28 while HPV-specific antibody is likely the major mechanism of protection against HPV infection following 29 immunization, available serological assays provide only a partial characterization of immune status, and no 30 measured immune response has been shown to define immediate or future protection against HPV infection 31 or associated disease. Future research efforts should therefore be directed towards correlating measures of 32 virus-specific immune memory with continued protection against infection with the HPV types in the 33 available vaccines, and towards determining the duration of cross-protection afforded by these vaccines 34 against HPV types other than those incorporated in the vaccines. 
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• Humoral immune responses to HPV measured by currently available 300 assays do not predict individual protection against disease.
301
• Following vaccination, immune memory is an important component 302 of ongoing protection.
303
• HPV vaccination induces some cross-protective immunity against 
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